• Rapport Therapeutics closed its $172.5 million offering of 2.25% convertible senior notes due 2032.
• The total includes full exercise of the underwriters’ option to purchase an additional $22.5 million of notes.
• Combined net proceeds from the notes, equity offerings and concurrent private placement totaled approximately $410.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020700PRIMZONEFULLFEED9867716) on November 02, 2026, and is solely responsible for the information contained therein.